Abstract:Type I interferons (IFNs) play essential roles in establishing and modulating host defense against microbial infection via induction of IFN-stimulated genes (ISGs) through Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathway. However, dysregulation of IFNs production and function could also mediate immune pathogenesis such as inflammatory autoimmune diseases and infectious diseases via aberrantly activating inflammatory responses or improperly suppressing microbial controls. Thus, IFN responses need to be tightly regulated to achieve protective immunity against microbial infection while avoiding harmful toxicity caused by improper or prolonged IFN signaling. Multiple levels of cellular and molecular events act in a cooperated manner to regulate IFN responses, in especial, post-translational modification (PTMs) of signaling molecules and epigenetic modification of gene expression programs are two important mechanisms for regulation of IFN signaling and thus critical for orchestrating IFN-mediated host immune response to the complex pathogenic or environmental stimuli. Conventional PTMs such as phosphorylation and polyubiquitylation, as well as numerous other PTMs including acetylation, ISGylation, SUMOylation and methylation have been shown to potently modulate type I IFN signaling transduction via targeting distinct signaling steps or components. Moreover, epigenetic mechanisms, such as histone modification, DNA methylation, non-coding RNAs play critical roles in regulating chromatin structure and function, leading to flexible and dynamic gene expression patterns downstream type I IFN signaling. Herein, we summarize the recent advances in the PTMs and epigenetic mechanisms in regulation of type I IFN signaling and responses. The involvement of dysregulated IFN signaling in inflammatory and autoimmune diseases are also discussed.

Type I interferon pathway in pediatric systemic lupus erythematosus

Type I Interferons in the Pathogenesis and Treatment of Sjögren’s Syndrome: an Update

Type I interferon in the pathogenesis of systemic lupus erythematosus

Immunological pathogenesis and treatment of systemic lupus erythematosus

Type I Interferons in Systemic Autoimmune Rheumatic Diseases: Pathogenesis, Clinical Features and Treatment Options

Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review

Potential role of RhoA GTPase regulation in type interferon signaling in systemic lupus erythematosus

Targeting interferons and their pathways in systemic lupus erythematosus

Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus

Type I IFN Drives Experimental Systemic Lupus Erythematosus by Distinct Mechanisms in CD4 T Cells and B Cells

Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?

The innate immune system in human systemic lupus erythematosus.

Interferon Inhibition in SLE: From Bench to Bedside

Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned

The crucial regulatory role of type I interferon in inflammatory diseases

Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells

Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies

Association Between Type I Interferon and Depletion and Dysfunction of Endothelial Progenitor Cells in C57BL/6 Mice Deficient in Both Apolipoprotein E and Fas Ligand.

Interferon pathway in SLE: one key to unlocking the mystery of the disease

Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus

Type I interferon associated epistasis may contribute to early disease-onset and high disease activity in juvenile-onset lupus